Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00161044
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 4, 2019
Sponsor:
Information provided by (Responsible Party):
MPRC, University of Maryland, College Park

Brief Summary:
The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.

Condition or disease Intervention/treatment Phase
Chronic Schizophrenia Drug: Galantamine Not Applicable

Detailed Description:
In this exploratory investigation, we propose to study the adjuvant therapeutic efficacy and safety of galantamine in 20 patients with chronic schizophrenia, who are maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment (see Table 1 for Selection Criteria). Assessments of neuropsychological performance will be made prior to the start of galantamine therapy and at study endpoint. Upon enrollment, neuropsychological tests will be administered by the study neuropsychologist, or a trained and supervised assessment technician; in fixed order, and according to standardized testing procedures. The following tests will be administered: (1) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (covering (a) verbal and visual episodic memory, (b) verbal response generation and self-monitoring, (c) auditory attention and working memory, and (d) sustained attention and psychomotor speed); and (2) Grooved Pegboard Test (motor speed). RBANS administration will be counterbalanced (using Forms A and B) across subjects and assessment points to prevent order effects. Remaining assessments will be administered at baseline, after galantamine titration, and at weeks 4 and 8 of galantamine treatment. Psychiatric symptoms and behavior will be assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), the Montgomery-Asberg Depression Rating Scale (MADRS); the Neuropsychiatric Inventory (NPI); the Clinical Global Impression Scale (CGI); and the Apathy Evaluation Scale (AES). Trained research nurses, psychologists and psychiatrists, will administer the symptom, behavior and functional scales with established inter-rater reliability. In this study, adverse effects will be monitored through self-reporting and observation. Vital signs will be collected on a weekly basis. Additionally, motor and movement side effects will be rated by trained research nurses, using the Extrapyramidal Symptom Rating Scale (EPRS), the Barnes Akathisia Scale (BAS); and the Abnormal Involuntary Movements Scale (AIMS). Following their initial neuropsychological assessment patients will enter a ¿three week galantamine titration phase¿ during which galantamine will be added to the stable regimen of antipsychotic medication according to the following titration schedule: 8 mg/day for the first week, followed by 16 mg/day in the second and 24 mg/day in the third week (Raskin et al., 2000). At the end of this titration phase, patients will be receiving the maximal allowable dose of galantamine (i.e., 24 mg/day) or an optimal dose (i.e., the highest tolerable dose devoid of significant side effects [e.g., 16 mg/day]). Moreover, at the end of this titration phase, patients will be administered the standard battery of rating instruments prior to entering an 8-week period of active treatment with the maximal or optimal adjuvant therapeutic dose of galantamine. During the active treatment phase, the standard battery of rating instruments will be administered at the end of the fourth and eighth week of active treatment. Patients admitted to the 364A Unit at Perry Point will have their charts reviewed to see if they meet the inclusion criteria for the study. After approval by the principal investigator the patient will be approached by a designated member of the research team for their interest in participating in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Study Start Date : September 2004
Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia




Primary Outcome Measures :
  1. This trial is an exploratory open-label trial; thus, several outcome measures are employed in order to detect possible therapeutic effects in the negative symptom domain of psychopathology


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fulfills DSM-IV criteria for schizophrenia.
  • Unable to achieve competitive employment status within the past five years.
  • Unable to live independently in the community.
  • Maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment.

Exclusion Criteria:

  • History of significant hepatic, renal, pulmonary, endocrine, active peptic ulcer disease or cardiovascular disease.
  • History of seizure disorder and/or head injury.
  • Co-morbid substance use/abuse disorder.
  • Received an investigational medication within the previous month.
  • Due to the risk of adverse effects on fetal development: women with any risk of becoming pregnant will be excluded from this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00161044


Locations
Layout table for location information
United States, Maryland
Maryland Psychiatric Research Center
Catonsville, Maryland, United States, 21228
Sponsors and Collaborators
University of Maryland, Baltimore
Investigators
Layout table for investigator information
Principal Investigator: Matthew Nelson, Pharm.D. MPRC
Layout table for additonal information
Responsible Party: MPRC, PI, University of Maryland, College Park
ClinicalTrials.gov Identifier: NCT00161044    
Other Study ID Numbers: H-23059
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: November 4, 2019
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Galantamine
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Parasympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents